Jennifer Doudna, who was awarded the Nobel Prize in Chemistry on Wednesday morning, along with collaborator Emmanuelle Charpentier, joined STAT at a San Francisco event last June when announcing a collaboration with the drug maker GlaxoSmithKline.
The collaboration between University of California, Berkeley, where Doudna is a professor, UC San Francisco, and GSK is to involve up to $67 million over five years. In the video below, Doudna and others talk about the relationship between researchers and drug companies, and the role that CRISPR, a gene-editing enzyme, will play in pharmaceutical research.
About the Author Reprints
CRISPR/CAS is a great research tool, and ….
a very much overhyped therapeutic one
the good old days, of people crowed in a confined space, with no masks. Oh wait! it was already in the midst of a pandemic!
I guess, even Nobel prize winners and STAT believed it was a hoax back then